血浆外泌体计数对脓毒症患者预后的预测价值
该前瞻性观察研究纳入2020年11月至2021年12月浙江医院ICU收治的26例脓毒症患者,入ICU第1、3、5、7天检测血浆外泌体计数,随访28天预后。死亡组入ICU第1天血浆外泌体计数显著高于存活组(16.96±9.11 vs. 5.20±2.42 ×10¹⁵/L,P<0.05)。多因素Logistic回归显示入ICU第1天血浆外泌体计数是28天死亡的独立危险因素(OR=1.385,95%CI 1.075-1.785,P=0.012),ROC曲线AUC为0.800(95%CI 0.449-1.000),最佳截断值14.50×10¹⁵/L时敏感度80.0%、特异度100%。
要点
- 脓毒症患者入ICU第1天血浆外泌体计数死亡组显著高于存活组(16.96±9.11 vs. 5.20±2.42 ×10¹⁵/L,P<0.05)。
- 入ICU第1天血浆外泌体计数是脓毒症患者28天死亡的独立危险因素(OR=1.385,95%CI 1.075-1.785,P=0.012)。
- 入ICU第1天血浆外泌体计数预测28天死亡的AUC为0.800(95%CI 0.449-1.000),最佳截断值14.50×10¹⁵/L时敏感度80.0%、特异度100%。
- 血浆外泌体计数<14.50×10¹⁵/L患者累积生存率显著高于≥14.50×10¹⁵/L者(Log-Rank检验:χ²=19.100,P<0.001)。
- 入ICU第1天血浆外泌体计数与SOFA评分、APACHE II评分、血乳酸、ALT、去甲肾上腺素剂量呈显著正相关(r值分别为0.572、0.585、0.463、0.411、0.696,均P<0.05),与MAP、氧合指数呈显著负相关(r值分别为-0.392、-0.496,均P<0.05)。
适用人群与场景
- 2020年11月至2021年12月浙江医院ICU收治的脓毒症患者26例,年龄、性别不限,记录基础疾病、感染部位等基线资料。
诊断标准与关键阈值
- 脓毒症诊断标准原文未具体列出,以入住ICU的脓毒症患者为研究对象。
- 以入ICU第1天血浆外泌体计数14.50×10¹⁵/L为最佳截断值,将患者分为<14.50×10¹⁵/L组和≥14.50×10¹⁵/L组进行生存分析。
处置流程与药物剂量
- 入ICU第1天记录性别、年龄、基础疾病、感染部位、平均动脉压(MAP)及病情严重程度评分,取静脉血检测血常规、血生化、降钙素原(PCT),取动脉血行血气分析,同时记录去甲肾上腺素(NA)用量。
- 入ICU第1、3、5、7天提取血浆外泌体,采用纳米颗粒跟踪分析仪检测外泌体数量。
- 观察终点为入ICU后28天死亡。
研究设计与关键结果
- 前瞻性观察性研究,纳入26例脓毒症患者,28天存活21例、死亡5例。
- 死亡组与存活组比较:MAP更低,SOFA评分、APACHE II评分、白细胞计数(WBC)、心肌肌钙蛋白I(cTnI)更高,氧合更差。
- 死亡组入ICU第1天血浆外泌体计数显著高于存活组(×10¹⁵/L:16.96±9.11 vs. 5.20±2.42,P<0.05);随后两组血浆外泌体计数持续下降,组间差异无统计学意义。
- Spearman相关分析:入ICU第1天血浆外泌体计数与SOFA评分(r=0.572)、APACHE II评分(r=0.585)、血乳酸(r=0.463)、丙氨酸转氨酶(ALT,r=0.411)、去甲肾上腺素剂量(r=0.696)呈显著正相关(均P<0.05),与MAP(r=-0.392)、氧合指数(PaO2/FiO2,r=-0.496)呈显著负相关(均P<0.05)。
- 多因素Logistic回归分析:入ICU第1天血浆外泌体计数是脓毒症患者28天死亡的独立危险因素(OR=1.385,95%CI 1.075-1.785,P=0.012)。
- ROC曲线分析:入ICU第1天血浆外泌体计数预测28天死亡的AUC为0.800(95%CI 0.449-1.000);最佳截断值14.50×10¹⁵/L时,敏感度80.0%,特异度100%。
- Kaplan-Meier生存曲线分析:血浆外泌体计数<14.50×10¹⁵/L患者累积生存率显著高于≥14.50×10¹⁵/L患者(Log-Rank检验:χ²=19.100,P<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症患者入ICU第1天血浆外泌体计数显著升高,与病情严重程度相关,可预测28天死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the predictive value of plasma exosome count for the prognosis of patients with sepsis.
METHODS: A prospective observational study was conducted. The patients with sepsis admitted to intensive care unit (ICU) of Zhejiang Hospital from November 2020 to December 2021 were enrolled as the study subjects. On the 1st day of admission to the ICU, the patient's gender, age, underlying disease, infection site, mean arterial pressure (MAP) and severity scores were recorded, and venous blood was taken for detecting the blood routine, blood biochemistry, and procalcitonin (PCT), and arterial blood was taken for blood gas analysis, simultaneously, the patient's noradrenaline (NA) dosage was recorded. On the 1st, 3rd, 5th, and 7th day of ICU admission, plasma exosomes were extracted, and the number of exosomes was detected by nanoparticle tracking analyzer. The endpoint of observation was the death of the patient 28 days after admission to the ICU. The differences in baseline data and plasma exosome counts of patients with different 28-day prognosis were analyzed and compared. The Spearman correlation method was used to analyze the correlation between plasma exosome counts and other clinical indicators. Binary multivariate Logistic regression analysis was used to screen the 28-day death risk factors of septic patients. The receiver operator characteristic curve (ROC curve) was plotted to analyze the predictive value of each index on the 28-day death of septic patients. The Kaplan-Meier method was used to analyze the 28-day survival curve.
RESULTS: A total of 26 patients with sepsis were enrolled, of whom 21 survived and 5 died on the 28th day. Compared with the survival group, the patients in the death group had lower MAP, higher sequential organ failure assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II) score, white blood cell count (WBC), cardiac troponin I (cTnI), and worse oxygenation. The plasma exosome count on the 1st day of ICU admission in the death group was significantly higher than that in the survival group (×1015/L: 16.96±9.11 vs. 5.20±2.42, P < 0.05). Subsequently, the plasma exosome counts in both groups continued to decrease, and there was no statistically significant difference between the two groups. Spearman correlation analysis showed that the plasma exosome count on the 1st day of ICU admission in septic patients was significantly positively correlated with SOFA score, APACHE II score, blood lactic acid (Lac), alanine aminotransferase (ALT) and NA dosage (r values were 0.572, 0.585, 0.463, 0.411, 0.696, all P < 0.05), and it significantly negatively correlated with MAP and oxygenation index (PaO2/FiO2; r values were -0.392 and -0.496, both P < 0.05). Multivariate Logistic regression analysis showed that plasma exosome count on the 1st day of ICU admission was an independent risk factor for 28-day death in septic patients [odds ratio (OR) = 1.385, 95% confidence interval (95%CI) was 1.075-1.785, P = 0.012]. ROC curve analysis showed that the area under the ROC curve (AUC) of plasma exosome count on the 1st day of ICU admission for predicting 28-day death in septic patients was 0.800 (95%CI was 0.449-1.000); when the optimal cut-off value was 14.50×1015/L, the sensitivity was 80.0% and the specificity was 100%. According to the optimal cut-off value of 1-day plasma exosome count, the patients were divided into two groups for Kaplan-Meier survival curve analysis, and the results showed that the cumulative survival rate of patients with plasma exosome count < 14.50×1015/L was significantly higher than that of patients with plasma exosome count ≥ 14.50×1015/L (Log-Rank test: χ 2 = 19.100, P < 0.001).
CONCLUSIONS: The plasma exosome count of septic patients is significantly increased on the 1st day of admission to the ICU, which is related to the severity, and can predict the risk of death at 28 days.
参考来源
- Li W, Pan Y, Yan J, et al. [Predictive value of plasma exosome count for the prognosis in septic patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39223881. doi:10.3760/cma.j.cn121430-20230717-00529
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。